论文部分内容阅读
目的探讨病毒唑联合654-2雾化吸入治疗喘憋性肺炎的疗效。方法治疗组在综合治疗的基础上,加用病毒唑1mg/kg,654-2 1mg/kg加入氯化钠溶液20ml联合雾化吸入,每日2次,每次20min,连用5d;对照组仅采用常规治疗。结果治疗组总有效率97.8%,对照组总有效率86.2%,两组差异有统计学意义(P<0.01);治疗组平均病程8.1d,对照组11.6d,差异有统计学意义(P<0.01)。结论采用病毒唑、654-2联合雾化吸入治疗喘憋性肺炎,疗效确切,为传统综合治疗喘憋性肺炎疗效欠佳者提供了一种新的治疗途径。
Objective To investigate the curative effect of ribavirin combined with 654-2 inhalation for asthmatic pneumonia. Methods The treatment group on the basis of comprehensive treatment, plus ribavirin 1mg / kg, 654-2 1mg / kg sodium chloride solution 20ml combined with inhalation, 2 times a day for 20min, once every 5d; control group only With conventional treatment. Results The total effective rate was 97.8% in the treatment group and 86.2% in the control group, with a significant difference between the two groups (P <0.01). The mean duration of treatment was 8.1 days in the treatment group and 11.6 days in the control group, with significant difference (P < 0.01). Conclusion Ribavirin and 654-2 combined with inhalation therapy for asthmatic pneumonia have a definite curative effect and provide a new therapeutic approach for the traditional treatment of asthmatic children with poor response to asthmatic pneumonia.